Glipizide in AKI and CKD

Reading File

Finding Sources

Searching PubMed

glipizide AND "renal impairment"

Reading File

Finding Sources

I have enough information from multiple authoritative textbooks. Here is a synthesized answer:

Glipizide in AKI and CKD

Pharmacokinetic Basis

Glipizide is a second-generation sulfonylurea with a short half-life of 2-4 hours. It is metabolized entirely in the liver (~90%) to completely inactive metabolites, with only the remainder excreted unchanged in the urine. This pharmacokinetic profile is the key reason it is preferred over other sulfonylureas in renal impairment.

Compare this to:

Glyburide: metabolites retain hypoglycemic activity and accumulate in renal failure - contraindicated when CrCl <50 mL/min
Glimepiride: active metabolites are renally cleared, requiring dose reduction
Chlorpropamide: long-acting and renally excreted - rarely used today for this reason
Katzung's Basic and Clinical Pharmacology, 16th Ed. (p. 1185)

In CKD

CKD Severity	Glipizide Use	Rationale
Mild-Moderate (eGFR 30-60)	Preferred sulfonylurea	Inactive metabolites; lower hypoglycemia risk vs. glyburide
Moderate-Severe (eGFR <30)	Use with caution, low dose	Insulin itself has prolonged action in CKD (reduced renal clearance of insulin); hypoglycemia risk remains elevated
End-stage / dialysis	Generally avoid; insulin preferred	Unpredictable glucose control; hypoglycemia risk high

Key points for CKD:

Glipizide and gliclazide are the preferred sulfonylureas in CKD because they lack active renally-cleared metabolites.
Even though glipizide itself is safe pharmacokinetically, the insulin it stimulates has a prolonged action in CKD (the kidney clears approximately 30-40% of circulating insulin), so hypoglycemia risk persists regardless of which sulfonylurea is chosen.
The Washington Manual recommends renal dose adjustment ("Yes, if CrCl <50 mL/min") with glipizide, noting it has "fewer problems in kidney disease" compared to glyburide.
Start at the lowest dose (2.5 mg/day) and titrate slowly.

Comprehensive Clinical Nephrology, 7th Ed. (p. 1072)
The Washington Manual of Medical Therapeutics (p. 898)
Lippincott Illustrated Reviews: Pharmacology (p. 813)

In AKI

AKI poses specific concerns beyond baseline CKD:

Acute loss of insulin clearance: Even if glipizide's own metabolites are inactive, any decline in eGFR during AKI prolongs the action of endogenous insulin stimulated by glipizide. This dramatically increases hypoglycemia risk.
Drug accumulation: While glipizide metabolites are inactive, if AKI also impairs hepatic perfusion (as in hepatorenal syndrome or cardiorenal syndrome), glipizide's hepatic metabolism itself may be compromised.
General recommendation - HOLD during AKI: All oral hypoglycemic agents, including glipizide, should be held during AKI. Insulin is the preferred agent for glycemic control in the acute inpatient setting because it is titratable and its dose can be adjusted rapidly as renal function changes.
Metformin vs. glipizide in AKI: While metformin is the agent more classically discussed in AKI (lactic acidosis risk), glipizide shares the concern of hypoglycemia risk during any acute deterioration in kidney function, as noted by Lippincott - "an acute deterioration in kidney function can reduce drug clearance at any time."

Rosen's Emergency Medicine (p. 3519-3524)

Relative Sulfonylurea Safety Ranking in Renal Disease

Safest to most dangerous:

Glipizide / Gliclazide - no active metabolites
Glimepiride - active metabolites but lower hypoglycemia risk than glyburide
Glyburide - avoid in renal impairment; active metabolites accumulate

Clinical Pearls

Glipizide is the sulfonylurea of choice when one must be used in renal impairment.
The extended-release (Glucotrol XL) formulation has a max dose of 20 mg/day in renal patients vs. 40 mg/day otherwise.
Monitor blood glucose closely; educate patients on hypoglycemia recognition.
In any patient on glipizide who develops AKI (e.g., from sepsis, contrast, NSAIDs, dehydration), discontinue glipizide and switch to insulin with close monitoring.
As eGFR falls below 30, most guidelines prefer insulin over any oral agent for safety and precision.

Bottom line: Glipizide is the preferred sulfonylurea in CKD due to its inactive metabolites and short half-life, but it is not risk-free - hypoglycemia remains a concern because renally-cleared insulin accumulates in CKD. In AKI, glipizide (and all oral agents) should be held in favor of insulin until renal function stabilizes.

Create a comparison table: glipizide vs. other sulfonylureas in CKD/AKI

Finding Sources

Reading File

I now have all the data needed. Here is the comparison table:

Sulfonylureas in CKD and AKI: Comparison Table

Feature	Glipizide	Gliclazide	Glimepiride	Glyburide (Glibenclamide)	Chlorpropamide
Generation	2nd	2nd	2nd	2nd	1st
Half-life	2-4 h (shortest)	10 h	5-9 h	1-2 h (but biologic effect ~24 h)	24-48 h
Hepatic metabolism	~90%	Complete	Complete	Yes	Partial
Active metabolites?	No (completely inactive)	No (completely inactive)	Weak/No	Yes (hypoglycemically active; renally cleared)	Yes (renally cleared)
Renal excretion of active drug/metabolites	Minimal (~10% unchanged)	Minimal	Low	Significant	High
CKD - Use permitted?	Yes - preferred	Yes - preferred	Caution; start low dose	Avoid (CrCl <50 mL/min)	Avoid
CKD dose adjustment	Yes, if CrCl <50 mL/min; start 2.5 mg/day	Start low; titrate slowly	Start at 1 mg/day; titrate slowly	Contraindicated in moderate-severe CKD	Contraindicated
eGFR threshold to avoid	<30 mL/min (use insulin instead)	<30 mL/min	<30 mL/min	<50 mL/min	Any significant CKD
AKI - Recommended action	Hold - switch to insulin	Hold - switch to insulin	Hold - switch to insulin	Hold (already contraindicated in most AKI patients)	Hold
Hypoglycemia risk in CKD	Lower (vs. glyburide); still present due to insulin accumulation	Lower; similar to glipizide	Intermediate	High - active metabolites accumulate	Very high - long-acting drug accumulates
Hypoglycemia risk in AKI	High (insulin clearance drops acutely)	High	High	Very high	Very high
Hepatic impairment	Contraindicated (primary elimination route)	Caution	Caution	Contraindicated	Avoid
US availability	Yes (Glucotrol, Glucotrol XL)	Not available in US	Yes (Amaryl)	Yes (DiaBeta, Glynase)	Yes (rarely used)
Max daily dose (normal renal function)	40 mg (IR); 20 mg (XL)	320 mg	8 mg	20 mg	500 mg
Overall safety rank in CKD	1st choice (with gliclazide)	1st choice (with glipizide)	2nd choice	Avoid	Avoid

Why Glipizide and Gliclazide Are Preferred

The shared advantage is the absence of renally-cleared active metabolites. In CKD/AKI, metabolite accumulation is the primary driver of prolonged, severe hypoglycemia. Glyburide's active metabolites can cause hypoglycemia lasting 24+ hours and are notoriously difficult to manage.

The Caveat That Applies to All Sulfonylureas in CKD

Even the "safer" agents carry hypoglycemia risk in CKD because:

Insulin clearance falls as GFR declines (the kidney clears ~30-40% of circulating insulin)
The insulin stimulated by any sulfonylurea therefore has a prolonged action in CKD
Uremia can also cause erratic glucose absorption from the gut

This means glipizide is relatively safer, not absolutely safe.

AKI: A Special Case

In AKI, the acute and unpredictable drop in GFR makes all oral agents unreliable. Insulin is the universal recommendation during AKI because:

It is titratable in real time
Its dose can be adjusted as GFR fluctuates
Blood glucose can be monitored and corrected rapidly

Any patient on glipizide who develops AKI (from sepsis, contrast nephropathy, volume depletion, or NSAIDs) should have glipizide held immediately and be transitioned to sliding-scale or basal-bolus insulin.

Sources: Katzung's Basic and Clinical Pharmacology 16e; Comprehensive Clinical Nephrology 7e; The Washington Manual of Medical Therapeutics; Lippincott Illustrated Reviews Pharmacology; NKF Primer on Kidney Diseases 8e

This is a shared conversation. Sign in to Orris to start your own chat.